MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
1.700
+0.030
+1.80%
After Hours: 1.720 +0.02 +1.18% 18:35 02/06 EST
OPEN
1.670
PREV CLOSE
1.670
HIGH
1.780
LOW
1.650
VOLUME
1.57M
TURNOVER
--
52 WEEK HIGH
2.710
52 WEEK LOW
0.3418
MARKET CAP
304.87M
P/E (TTM)
-5.5105
1D
5D
1M
3M
1Y
5Y
1D
Century Therapeutics Files Prospectus For Offering 176.087M Common Shares
Benzinga · 1d ago
Century Therapeutics files to sell 176.09M shares of common stock for holders
TipRanks · 1d ago
CENTURY THERAPEUTICS FILES PROSPECTUS TO OFFER, RESALE FROM TIME TO TIME BY SELLING STOCKHOLDERS OF UP TO 176.1 MLN SHARES OF COMMON STOCK
Reuters · 1d ago
Weekly Report: what happened at IPSC last week (0126-0130)?
Weekly Report · 4d ago
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 01/30 12:05
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 01/27 21:05
Are Biotech And Pharma Stocks Poised To Keep Climbing After Hitting 52-Week Highs?
NASDAQ · 01/27 10:34
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/26 21:05
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies and autoimmune diseases. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-308, CNTY-341, CNTY-107, and CNTY-104. Its lead product candidate CNTY-101 is a CAR-iNK cell therapy with six precision gene edits in a Phase I clinical trial for patients with B-cell mediated autoimmune diseases. CNTY-308 is a CD19-targeted, iPSC derived CAR T cell therapy. CNTY-341 is a dual-targeted CD19 and CD22 iPSC-derived CAR-T cell therapy.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.